Menu
Menu
Question:
What biosimilars have been approved by the FDA, and how are they coded?
Answer:
Currently, Zarxio (reference product: Neupogen) and Inflectra (reference product: Remicade) are the only approved biosimilars, but additional Food & Drug Administration (FDA) approvals for biosimilars should occur in the near future.
Providers administering these products will need to remain current with coding and billing guidelines to ensure accurate assignment of HCPCS and the use of manufacturer-specific modifiers, such as the following:
| Q5101 | Injection, Filgrastim (G-CSF), biosimilar, 1 microgram Modifier ZA—Novartis/Sandoz) |
| Q5102 | Injection, Infliximab, biosimilar, 10 mg Modifier ZB—Pfizer/Hospira |
CPT® copyright 2023 American Medical Association (AMA). All rights reserved.
Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
CPT is a registered trademark of the American Medical Association.
Subscribe to receive our News, Insights, and Compliance Question of the Week delivered right to your inbox.
Address:Â 5874 Blackshire Path, #13, Inver Grove Heights, MN 55076
Phone:Â (800) 252-1578
Email:Â support@medlearnmedia.com
Hours:Â 9am – 5pm CT
Copyright © 2024 MedLearn Publishing. Powered by MedLearn Media.
Happy World Health Day! Our exclusive webcast, ‘2024 SDoH Update: Navigating Coding and Screening Assessment,’ Â is just $99 for a limited time! Use code WorldHealth24 at checkout.